CSL and uniQure un­veil three-year da­ta for one-time he­mo­phil­ia B gene ther­a­py that costs $3.5M

With its $3.5 mil­lion price tag, CSL Behring and uniQure’s one-off he­mo­phil­ia B gene ther­a­py Hem­genix is one of the world’s most ex­pen­sive ther­a­pies. On …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.